Grifols reported Q3 Biopharma growth of 10.3% and group revenue growth of 8.4%, both at constant currency, with adjusted EBITDA of €538 million and a 26.4% margin in the quarter. Total net leverage stood at 3.98x. The Board announced a 2026 interim dividend of €0.15 per share, payable in early December 2026.
GRFS · Grifols SA
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 31%
- Last earnings
- Nov 2, 2026
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Grifols's board approved an interim dividend on account of 2026 profit of euro 0.15 per share, to be paid on 4 December 2026. Banco Bilbao Vizcaya Argentaria (BBVA) will act as paying agent.
Grifols reported Q3 2026 revenue of EUR 2,040 million, up 8.4% year-over-year at constant currency, and net profit of EUR 162 million, up 27.9%, while confirming full-year 2026 guidance.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GRFS
this stock
Grifols SA
|
$5.55B | -12.8% | — | — | 0.9% |
|
LLY
ELI LILLY & Co
|
$1.27T | +25.3% | +44.7% | 43.7 | 0.8% |
|
JNJ
Johnson & Johnson
|
$651.11B | +30.7% | +6.0% | 41.1 | 0.7% |
|
ABBV
AbbVie Inc.
|
$505.89B | +25.3% | +8.6% | 49.3 | 0.9% |
|
MRK
Merck & Co., Inc.
|
$329.65B | +27.0% | +1.3% | 137.9 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 2, 2026
- This year
- 14
Grifols reported Q3 2026 revenue of EUR 2,040 million, up 8.4% year-over-year at constant currency, and net profit of EUR 162 million, up 27.9%, while confirming full-year 2026 guidance.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GRFS | -6.2% | +7.8% | +6.8% | +0.6% | -12.8% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +2.4% | +17.0% | +16.0% | +9.3% | -14.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.